How do you pay?

How to pay the least

Ask for the cash price

Bixlenvo

We didn’t find one.

  1. Ask your pharmacy for Bixlenvo’s cash price, and one or two other pharmacies too.
  2. Bixlenvo’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP). Or call 1-800-226-2056.

See if you qualify 

Compare every option

Question
Brand nameBixlenvo
Authorized genericbictegravir and lenacapavir
Regular genericbictegravir and lenacapavir
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Bixlenvo?
The original
–
–

Brand nameThe maker’s card

Gilead Advancing Access Co-pay Savings Program

Savings card from Gilead Sciences

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a fill

Sign up on bixlenvo.com 

Or call 1-800-226-2056.

In the maker’s words

“If eligible, you may be able to pay as little as $0 for your co-pay.”

From the maker’s offer on bixlenvo.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Bixlenvo itself, from the same company, sold without the brand name, and usually for less. For now Bixlenvo is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

BIXLENVO, a two-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and lenacapavir (LEN), an HIV-1 capsid inhibitor, is indicated as a complete regimen for the treatment of HIV-1 in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO.

Source: the FDA label for Bixlenvo (Gilead Sciences, Inc.), August 27, 2026. Full label on DailyMed 

Good to know